Hinds A, Sheehan A G, Machida H, Parsons H G
Department of Pediatrics, University of Calgary, AB, Canada.
Diabetes Res. 1991 Oct;18(2):69-78.
Pancreatic endocrine function was studied in 50 patients with cystic fibrosis (CF) and 15 healthy controls by measuring glucose, insulin, C-peptide, glucagon and gastro-inhibitory polypeptide responses to an oral glucose tolerance test (OGTT). Biochemical and clinical parameters were also measured, including glycosylated hemoglobin A1, serum immunoreactive trypsin, fasting urinalysis, pulmonary function, percentage body fat and 3-day dietary records. According to National Diabetes Data Group (NDDG) criteria, 6 CF patients had impaired glucose tolerance (ICF), with elevated serum glucose concentrations and reduced and delayed insulin secretion compared with control (CON) subjects, although none were overtly diabetic. Although the remaining 44 CF patients (NCF) did not meet NDDG criteria for impaired glucose tolerance, mean area under the concentration curve (AUC) for glucose was greater than control values and AUC for insulin diminished. HbA1 levels in the 2 CF groups were greater than that of controls subjects, but there was little difference between ICF and NCF groups. C-peptide levels paralleled those of insulin for the 3 groups throughout OGTT. There was little difference in GIP secretion between groups, and the enteroinsular axis was intact in the control and NCF groups and slightly increased in the ICF group. Basal glucagon concentrations and AUC for glucagon during OGTT were similar for the 3 groups, but glucose-induced glucagon suppressibility i.e., basal to nadir change in each subject, was reduced in the ICF group. Serum IRT concentration was significantly lower in the ICF and NCF groups compared to control subjects, and was lowest in the ICF group. A strong correlation was observed in the ICF group between FEF25-75 and AUC for insulin, as well as HbA1 level and AUC for glucose. The prevalence of impaired glucose tolerance in 50 CF patients was 12%. Despite extensive comparisons of biochemical and clinical parameters with endocrine function in this population, we were unable to define reliable criteria for predicting glucose intolerance.
通过测量口服葡萄糖耐量试验(OGTT)后的葡萄糖、胰岛素、C肽、胰高血糖素和胃肠抑制多肽反应,对50例囊性纤维化(CF)患者和15名健康对照者的胰腺内分泌功能进行了研究。还测量了生化和临床参数,包括糖化血红蛋白A1、血清免疫反应性胰蛋白酶、空腹尿液分析、肺功能、体脂百分比和3天饮食记录。根据美国国家糖尿病数据组(NDDG)标准,6例CF患者存在糖耐量受损(ICF),与对照组(CON)相比,血清葡萄糖浓度升高,胰岛素分泌减少且延迟,尽管无明显糖尿病患者。虽然其余44例CF患者(NCF)不符合NDDG糖耐量受损标准,但葡萄糖浓度曲线下平均面积(AUC)大于对照值,胰岛素AUC降低。两个CF组的HbA1水平均高于对照组,但ICF组和NCF组之间差异不大。在整个OGTT过程中,三组的C肽水平与胰岛素水平平行。各组间GIP分泌差异不大,对照组和NCF组的肠胰岛轴完整,ICF组略有增加。三组的基础胰高血糖素浓度和OGTT期间胰高血糖素的AUC相似,但ICF组葡萄糖诱导的胰高血糖素抑制能力(即每个受试者基础值到最低点的变化)降低。与对照组相比,ICF组和NCF组的血清IRT浓度显著降低,ICF组最低。在ICF组中,观察到用力呼气流量25%-75%(FEF25-75)与胰岛素AUC以及HbA水平与葡萄糖AUC之间存在强相关性。50例CF患者中糖耐量受损的患病率为12%。尽管对该人群的生化和临床参数与内分泌功能进行了广泛比较,但我们仍无法确定预测葡萄糖不耐受的可靠标准。